A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis — ASCEND in SPMS

Secondary Progressive Multiple Sclerosis Clinical Trial

Official title:
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis, With Optional Open-Label Extension

Status Terminated

Clinical Trial Summary

This is a Phase 3b, multicenter, international study conducted in 2 parts. Upon completion of the placebo-controlled period (Part 1), participants will have the option of enrolling in a 2-year open-label extension (Part 2).

Part 1: The primary objective of the study is to investigate whether treatment with natalizumab slows the accumulation of disability not related to relapses in participants with secondary progressive multiple sclerosis (SPMS).

The secondary objectives of Part 1 of this study are to determine the proportion of participants with consistent improvement in Timed 25-Foot Walk (T25FW), the change in participant-reported ambulatory status as measured by the 12-item MS Walking Scale (MSWS-12), the change in manual ability based on the ABILHAND Questionnaire, the impact of natalizumab on participant-reported quality of life using the Multiple Sclerosis Impact Scale-29 Physical (MSIS-29 Physical), the change in whole brain volume between the end of study and Week 24 using magnetic resonance imaging (MRI) and the proportion of participants experiencing progression of disability as measured by individual physical Expanded Disability Status Scale (EDSS) system scores.

Part 2: The primary objective of Part 2 of the study is to evaluate the safety profile of natalizumab in participants with SPMS.

The secondary objectives of Part 2 of the study are to investigate long-term disability (based on clinical or patient-reported assessments) in participants with SPMS receiving natalizumab treatment for approximately 4 years and to assess change in brain volume and T2 lesion volume.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Multiple Sclerosis
Multiple Sclerosis, Chronic Progressive
Neoplasm Metastasis
Sclerosis
Secondary Progressive Multiple Sclerosis

Clinical Trial Details

NCT number	NCT01416181
Study type	Interventional
Source	Biogen
Contact
Status	Terminated
Phase	Phase 3
Start date	September 2011
Completion date	April 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04239664` - Acceptance Based Telephone Support When Transitioning to SPMS	N/A
Active, not recruiting	`NCT04411641` - Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)	Phase 3
Completed	`NCT02549703` - Mitochondrial Dysfunction and Disease Progression
Withdrawn	`NCT01181089` - Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)	Phase 1/Phase 2
Active, not recruiting	`NCT03471338` - Neuropsychological Management of Multiple Sclerosis: Benefits of a Computerised Semi-autonomous At-home Cognitive Rehabilitation Programme	N/A
Withdrawn	`NCT05029609` - Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS	Phase 1
Completed	`NCT02228213` - Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis	Phase 2
Terminated	`NCT02296346` - Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple Sclerosis	N/A
Completed	`NCT00559702` - Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)	Phase 1
Terminated	`NCT03283826` - Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis	Phase 1/Phase 2
Completed	`NCT02253264` - A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients	Phase 1
Completed	`NCT01737372` - A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis	N/A
Completed	`NCT00257855` - A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis	Phase 2
Recruiting	`NCT06292923` - A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients	Phase 2
Active, not recruiting	`NCT01228396` - AIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple Sclerosis	Phase 2
Completed	`NCT03896217` - Simvastatin in Secondary Progressive Multiple Sclerosis	Phase 2
Completed	`NCT02495766` - Autologous Mesenchymal Stromal Cells for Multiple Sclerosis	Phase 1/Phase 2
Completed	`NCT00813969` - Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS	Phase 1
Completed	`NCT01077466` - Natalizumab Treatment of Progressive Multiple Sclerosis	Phase 2
Terminated	`NCT00146159` - Study Evaluating Mitoxantrone in Multiple Sclerosis	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.